Potassium Iodide Tablets K1 - 130 mg - Radiation Protection

Description

In Stock Now - Fresh stock from the Manufacturer with an expiration date of 2018

Radiation Protection

Approved by the FDA and recommended by the CDC, iOSAT is the first radiation protective tablet available to the general public. Experts agree that its prompt use would be the most effective measure available to protect millions of people who would be at risk in a nuclear accident or under a radiation threat from a terrorist nuclear weapon. These FDA approved tablets contain potassium iodide (KI) which provides virtually complete protection from radioactive iodine (RAI), the contaminant that causes thyroid cancer. Should RAI ever escape, the health effects would be disastrous. Those at highest risk are infants and children, as well as pregnant and nursing females.

According to the FDA, there are no other OTC (over the counter) drugs with the same active ingredient, strength and dosage form/route as iOSAT.

Investigators, including the UN, the World Health Organization (WHO), the US FDA, the US Nuclear Regulatory Commission (NRC) and The American Thyroid Association, uncovered the following unexpected finding at Chernobyl:

"Thyroid cancer was the only prominent health problem to effect the general population. Although the accident released many types of radioactive isotopes to the environment, all of the injuries (to people located more than a few miles from the reactor) were limited to just the effects of radioactive iodine."

Each packet contains 14 tablets of 130mg, individually foil sealed. Shelf life is 7 years.

FDA Guidelines for Potassium Iodide

FDA Instructions on use of Potassium Iodide tablets for Children

IOSAT Product Patient Insert

Features

individually foil sealed packet of 14 tablets
130 mg each
FDA approved
CDC recommended
can be taken by adults, children, & infants
7-year shelf life

Potassium Iodide Tablets (KI), 130 mg iOSAT, Radiation Protection

Potassium Iodide Tablets (KI), 130 mg iOSAT, Radiation Protection